ACR Highlights… EULAR 2024 Highlights – People with Arthritis / Rheumatism across Europe (PARE) 21 Jul 202421 Nov 2026 Author: Sladjana Rumpl Tunjic Beesley et al. (OP0102) presented the development and implementation of novel and innovative approaches for raising awareness of childhood arthritis. Raising awareness that children and young people get arthritis is…
ACR Highlights… ACR Convergence Highlights 2023 – Basic Research I: Genetics, cartilage/synovium, osteoimmunology, animal models 9 Dec 202321 Nov 2026 Author: Rami Bechara Hou et al. (0733) utilised CRISPR/Cas9 technology to identify cell type-specific functional variants that regulate the Type I interferon pathway in lupus. Notably, they discovered the negative regulatory effect…
ACR Highlights… ACR Convergence Highlights 2023 – Basic Research II: Immunity, Immunology 9 Dec 202321 Nov 2026 Author: Latika Gupta Ghossan et al. (0732) established that while B cell depletion is associated with a better response to RTX at the start of treatment, the persistence of complete B cell depletion is not…
ACR Highlights… ACR Convergence Highlights 2023 – Rheumatoid Arthritis: Clinical (therapeutic) 9 Dec 20239 Dec 2023 Author: Victoria Konzett Cope et al. (0835) investigated the efficacy of T-cell co-stimulation with Abatacept on prevention of disease onset in an autoantibody-positive population with arthralgia at risk of developing RA,…
ACR Highlights… ACR Convergence Highlights 2023 – Spondyloarthritis I: Clinical (non-therapeutic) 9 Dec 20239 Dec 2023 Author: Olivier Fakih Michel et al. (2222) compared patients with a SpA + IBD codiagnosis versus those with only one diagnosis in a retrospective monocentric study. 62 patients with a…
ACR Highlights… ACR Convergence Highlights 2023 – Spondyloarthritis II: Clinical (therapeutic) 9 Dec 20239 Dec 2023 Author: Bayram Farisogullari Kivitz et al. (0776) investigated the long-term efficacy, safety, and tolerability of intravenous (IV) secukinumab (SEC) in patients with active PsA through 52 weeks in a randomised,…
ACR Highlights… ACR Convergence Highlights 2023 – SLE and APS 9 Dec 20239 Dec 2023 Author: Anastasia Madenidou Schett et al. (0607) followed up 8 SLE patients who received treatment with CD19 CAR T cell therapy. Five patients had a follow-up of more than one year…
ACR Highlights… ACR Convergence Highlights 2023 – Metabolic & Crystal arthropathies 9 Dec 20239 Dec 2023 Author: Dálifer Freites Núñez Tedeschi et al. (0234) performed a secondary analysis using data from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial. Among 6183 participants in this analysis,…
ACR Highlights… ACR Convergence Highlights 2023 – Other Connective Tissues Diseases and Vasculitis 9 Dec 20239 Dec 2023 Author: Lisa Christ Bergmann et al. (2598) observed stabilisation of disease activity in 3 systemic sclerosis (Ssc) patients treated with CD19 CAR T-cells at 6 months follow-up. Taubmann et al.…
ACR Highlights… ACR Convergence Highlights 2023 – Rare & Autoinflammatory diseases 9 Dec 202321 Nov 2026 Author: Dálifer Freites Núñez Brown et al. (0280) characterized the largest cohort of patients suffering from Susac Syndrome, a rare autoimmune condition causing microvascular occlusions in the brain, retina and inner ear leading to…